Drug Profile
Research programme: myocardial infarction therapy - BioLineRx/Tel Aviv University/Tel Hashomer
Alternative Names: EDP 15Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Tel Aviv University; Tel Hashomer Medical Research Infrastructure and Services
- Developer BioLineRx; Tel Aviv University; Tel Hashomer Medical Research Infrastructure and Services
- Class
- Mechanism of Action Collagen stimulants; Extracellular matrix protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Myocardial-infarction in Israel